Many genetic mutations in MDS, such as TP53, RUNX1, and ETV6, are suboptimal biomarkers for detecting relapse of MDS, but none have been applied for the detection of MRD in the HSCT setting [32–35]. The gene discussed is TP53; the disease is myelodysplastic syndrome.